Clinical Trials
294 trialsGraft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Fred Hutchinson Cancer Center
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
HESTIA
Baylor College of Medicine
Flu-Mel-Vel
Hackensack Meridian Health
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)
Fred Hutchinson Cancer Center
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma
H. Lee Moffitt Cancer Center and Research Institute
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation
Medical College of Wisconsin
A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD)
M.D. Anderson Cancer Center
CD30 CAR for CD30+ NSGCT
UNC Lineberger Comprehensive Cancer Center
Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts
H. Lee Moffitt Cancer Center and Research Institute
Off-the-shelf NK Cells + SCT for Myeloid Malignancies
M.D. Anderson Cancer Center
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
Thomas Jefferson University
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation
Case Comprehensive Cancer Center
ICLL07GAI
French Innovative Leukemia Organisation
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Thomas Jefferson University
Epigenetic Reprogramming in Relapse/Refractory AML
Therapeutic Advances in Childhood Leukemia Consortium
Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas
M.D. Anderson Cancer Center
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Ohio State University Comprehensive Cancer Center
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
Masonic Cancer Center, University of Minnesota
Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma
H. Lee Moffitt Cancer Center and Research Institute
NYM
Jonsson Comprehensive Cancer Center
Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)
Masonic Cancer Center, University of Minnesota
Haplo Peripheral Blood Sct In GVHD Prevention
Massachusetts General Hospital
UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep
Masonic Cancer Center, University of Minnesota
Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia
City of Hope Medical Center
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD
Fred Hutchinson Cancer Center
Reduced Intensity Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Thomas Jefferson University
PACIFICO
University of Liverpool
UKALL14
University College, London
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
Vanderbilt-Ingram Cancer Center
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
City of Hope Medical Center
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor
Memorial Sloan Kettering Cancer Center
TIL Therapy for Metastatic Renal Cell Carcinoma
Herlev Hospital
Haploidentical Stem Cell Transplant with Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL
Cedars-Sinai Medical Center
Adoptive Cell Therapy Across Cancer Diagnoses
Herlev Hospital
FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
Stanford University
Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma
M.D. Anderson Cancer Center
Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies
M.D. Anderson Cancer Center
Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS
University of Pittsburgh
AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders
City of Hope Medical Center
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
M.D. Anderson Cancer Center
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children
Fred Hutchinson Cancer Center
Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)
M.D. Anderson Cancer Center